While serving as vice president at Vertex Pharmaceuticals in the US, he led a team of 200 RRD workers in a collaborative project with pharmaceutical industry giant Novartis. He was in charge of a project to develop kinase inhibitors, which have anti-cancer and anti-inflammatory properties, as well as the ability to suppress adverse drug reactions.
他擔任美國維特製藥公司副總裁時。曾帶領 200 位研發人員與諾華大藥廠合作，負責開發抗癌、抗發炎、抗排斥藥物的磷酸抑制劑。